Biotech Support Group primary focus is to be the leader in genomic and proteomic sample preparation and enrichment products. These products are based upon patented proprietary technology. Revenues are generated through the sale of high value consumable bottled reagents and application kits primarily targeting the life science academic and industrial research community. The company is also committed to develop the entire process technology including new materials for identification of disease-associated proteins for medical diagnosis in collaboration with ProFact, Inc.

Phone: 732-246-3110
Fax: 732-246-3118
Email: sales@biotechsupportgroup.com
Mail: Biotech Support Group, LLC
Technology Centre of New Jersey
675 Highway One, North Brunswick, NJ, 08902

Cambrex Corporation, a leading supplier of human, health and bioscience products occupies 42,000 sf. for its Cambrex Center of Technical Excellence. The Cambrex Center of Technical Excellence provides dynamic synergies in scientific and engineering knowledge to help its customers optimize drug leaders, determine synthesis pathways, and develop and optimize processes in a cGMP environment. In order to make space more affordable for Cambrex, the Technology Centre has invested over $3,000,000 towards the cost of constructing the Cambrex Center of Technical Excellence.

Chromocell is a life sciences company commercializing a novel technology that significantly accelerates drug discovery and development. The technology allows the rapid and automated production of stable cell lines expressing or suppressing multiple genes, which in turn enables the production of powerful cell based assays and products for use in drug screening and development. Cell based assays are increasingly relied upon and beginning to define a paradigm shift in their favor. Chromocell enables access to the full potential of cell based assays by obviating the most tedious and time consuming steps that hindered the crafting of the most robust and efficient designs. Chromocell will be a leader in the production of stable cell lines and highly crafted cell based assays and products.

The Chubb Institute has leased approximately 24,000 square feet within the Tech Centre for consulting services and classroom space to train businesses and students in computer technologies.

ClinTech Research is a New Jersey, USA based Contract Research Organization (CRO) with a wholly owned subsidiary in India. We offer Clinical Data Management (including Clinical IT), and Regulatory Pre-Clinical Toxicology services to Pharmaceutical and Biotechnology companies through our operations in the USA and in India. We also manage clinical trials in India as part of the studies conducted in the USA and in India. Our strong team of managers in the USA work as a single-point-of-contact liaison for our clients to handle all offshore activities; and assist our clients in achieving their strategic and project goals.

Phone: 732-623-4193; 732-828-1200
Fax: 732-601-2586
Email: info@clintechresearch.com http://www.clintechresearch.com

Ennova MedChem Group , Inc. is a privately held company focusing on utilizing its core technology in chemistry and life sciences to create a broad range of commercial applications. The scope of products and services we provide include but not restricted to the following sectors: special chemical R&D, custom synthesis, pharmaceutical intermediate manufacturing, and contract research, pharmaceutical development, consumer health and food product development and manufacturing, contract distribution and marketing, international trade and consulting services.

Neurotez, Inc. is a private corporation, formed to study and advance treatments for degenerative disorders of the central nervous system (CNS). Utilizing an integrated platform that spans activities from discovery to proof of concept clinical trials, Neurotez aims to identify and facilitate the commercialization of safe and efficacious CNS drugs. Neurotez’s lead biopharmaceutical is a potential therapeutic for Alzheimer's disease patients, currently in the planning for clinical trials. Additional candidates, identified by exploiting proprietary screening technologies are in the discovery stage.

Orthocon is a privately held Specialty Pharmaceutical and Medical Device Company focused on the development of innovative products for Orthopaedic and Spine Surgery. The Company's product development activities are based on its proprietary Syntinate™ Synthetic Absorbable Technology comprised of natural and synthetic orthobiologic compounds with precise absorption and release attributes for interoperative drug delivery.

PlasmaSol Corp., a biosciences R&D company, is developing sterilization and infection control solutions for health care facilities based on its gas plasma chemistry and microbiology expertise. The company’s basic atmospheric-pressure, room-temperature gas plasma technology was developed at Stevens Institute of Technology.

ProFACT applies its proprietary profiling system, ProFILE™, to drug development issues of efficacy and toxicity - ADRs (Adverse Drug Reactions), and to disease biomarkers and progression metrics. ProFACT is initially focused on cancer drugs and metrics through alliances with institutional and academic drug development programs. The ProFACT Proteomics™ platform (patent pending) is the back bone of the ProFILE™ system and the ProPREP™ line of consumables products for proteomic research, marketed internationally.

Rutgers Technology Center II, a 26,000-square-foot facility that will house advanced development laboratories where university researchers will collaborate with technical experts in startup ventures, established corporations and government agencies. Together they will define new capabilities for wireless computer and cell phone networks, invent lightweight yet powerful energy sources for products ranging from body implants to hybrid cars, and formulate targeted drug therapies to relieve chronic diseases.

Semorex, Inc. is a privately held development stage company focused on developing point-of-care diagnostic and field detection devices that utilize its proprietary molecularly imprinted polymers for selective molecular recognition as sensing elements on sensor modules. These products will provide rapid and accurate real time information to clinicians and emergency response teams in military and civilian operations where immediate action is essential. In addition to saving critical time, Semorex products will lower the costs of and simplify the practice of detection and diagnosis. The Company’s efforts are focused on developing products for markets with significant unmet needs and substantial growth potential. The Company’s breakthrough technology, which combines proprietary advances in polymer chemistry and immunochemistry, enables it to make molecularly imprinted polymers (MIPs) having selective molecular recognition that mimic the affinity and sensitivity of antibodies. While antibodies display exquisite selectivity, they are not effective for a significant number of targets that are non-immunogenic: lipids, carbohydrates, and small molecules. Therefore, we focus on disease markers and detection targets chosen from these classes of compounds.